Clinical Progress

Exploring Cadonilimab's R&D successes and its clinical results at the 2024 AACR

18 April 2024
4 min read

PD-1 inhibitors plus chemo have shown efficacy in first-line treatment of advanced G/GEJ adenocarcinoma; however, the survival benefits are limited in patients with low PD-L1 expression. On April 7, 2024, the latest clinical data of Cadonilimab (the PD-1/CTLA-4 bispecific antibody) plus chemo were reported in 2024 AACR.

Cadonilimab's R&D Progress

Cadonilimab is a bispecific antibody drug that targets CTLA4 x PD-1. It has been approved for use in various therapeutic areas, including neoplasms, urogenital diseases, digestive system disorders, respiratory diseases, endocrinology and metabolic disease, mouth and tooth diseases, otorhinolaryngologic diseases, skin and musculoskeletal diseases, immune system diseases, hemic and lymphatic diseases, and other diseases. 

According to the Patsnap Synapse, Cadonilimab has received approval in the highest phase globally and in China. And the clinical trial distributions for Cadonilimab are primarily in the United States, China and Australia. The key indication is Advanced Hepatocellular Carcinoma. 

Detailed Clinical Result of Cadonilimab

This randomized, double-blind, placebo-controlled phase 3 study (NCT05008783) was aimed to evaluate the efficacy and safety of cadonilimab, the PD-1/CTLA-4 bispecific antibody, plus chemo vs chemo alone as the first-line treatment in G/GEJ adenocarcinoma. 

In this study, eligible pts were adults with untreated, unresectable, locally advanced, or metastatic G/GEJ adenocarcinoma, regardless of PD-L1 expression. Pts were randomized 1:1 to receive cadonilimab (10mg/kg Q3W) plus chemo (Q3W) or placebo plus chemo. Randomization was stratified by ECOG PS score (0 vs. 1), PD-L1 status (visualized combined positive score by Ventana SP263, vCPS<5% vs ≥5%), and hepatic metastasis (yes vs no). The primary endpoint was OS in the ITT population. The cutoff date was Aug 18, 2023.

The result showed that 610 pts were enrolled from 76 study centers and randomized to Cadonilimab + chemo (n=305) or placebo + chemo (n=305) with a median follow-up of 18.69 months (range 0.0-22.7). The median OS was longer in the cadonilimab group versus the placebo group (HR 0.62 [95%CI: 0.50-0.78], mOS 15.0 vs 10.8 mo; P<0.001). OS benefits were consistently observed at all pre-specified CPS cutoffs, especially in patients with low PD-L1 expression, which still showed survival advantage. Longer PFS was observed in the cadonilimab group (HR 0.53 [95%CI: 0.44-0.65], mPFS 7.0 vs 5.3 mo; p<0.001). The ORR was 65.2% vs 48.9%, respectively, with a median DOR of 8.8 vs 4.4 months. Grade ≥3 treatment-related AEs occurred in 71.8% of pts who received cadonilimab and 60.5% of pts who received placebo; no new safety signals were observed.

It can be concluded that Cadonilimab plus chemo showed significant improvement in OS and PFS regardless of PD-L1 status and manageable safety profile, which could be a new standard first-line treatment option for advanced G/GEJ adenocarcinoma.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Fresenius Boosts Its Pharma Performance and Introduces Tyenne®, the Third Biosimilar to Receive U.S. Approval
Latest Hotspot
3 min read
Fresenius Boosts Its Pharma Performance and Introduces Tyenne®, the Third Biosimilar to Receive U.S. Approval
18 April 2024
Fresenius has declared through its subsidiary, Fresenius Kabi, the launch of Tyenne (tocilizumab-aazg) in the United States.
Read →
Atezolizumab: A Quick Look at Its R&D Progress and Clinical Results from the 2024 AACR
Atezolizumab: A Quick Look at Its R&D Progress and Clinical Results from the 2024 AACR
18 April 2024
On April 5, 2024, the latest clinical trial of Atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk LA SCCHN were reported in 2024 AACR.
Read →
What is Berlin Patient?
"What" Series
2 min read
What is Berlin Patient?
18 April 2024
The "Berlin Patient" refers to Timothy Ray Brown, an American man who was known as the first person to be cured of HIV/AIDS.
Read →
An analysis of ASKC202's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
An analysis of ASKC202's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
18 April 2024
On April 5, 2024, the AACR reported the latest clinical trial results of ASKC202, illustrating its potential clinical benefits and setting the stage for further exploration.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.